2 days ago
Associate Professor Raymond Wong, from the Centre for Eye Research Australia (CERA) and University of Melbourne, received a $40,000 grant from Retina Australia in 2020 for the project:
“Development of regenerative therapy for retinitis pigmentosa using cellular reprogramming”.
The pilot data from this grant enabled Associated Professor Wong to subsequently obtain larger grants and enable other spin-off cell reprogramming projects to treat retinal degeneration to further its research impact.
Over $4.5M has been awarded to date, following the 2020 Retina Australia grant, representing a significant funding leverage of 114 times.

Research Impact
- 3 patents on the cellular reprogramming technologies developed in this project, led to the reprogrammimg of the stem cells within the retina (the Muller glia) to regenerate retinal neurons.
- To further develop this into a novel gene therapy, a spin off biotech start-up company, Mirugen, was established to commercialise and translate the research to the clinic.
- Mirugen is focused on developing a gene therapy to stimulate retinal regeneration to treat vision loss in blind patients.
- As a spin-out company from the Centre for Eye Research Australia, Mirugen has raised approximately $7M of funding to date, including support from Medical Research Future Fund (MRFF)’s national biotech incubator programs CUREator and CUREator+, as well as additional commercial investments.
The gene therapy work has received significant media attention, and the team has also presented its work in research seminars, national and international meetings including most recently:
- 2025 – Radio interview with 2RPH radio – an Australian radio station for those with reading difficulties
- 2025 – News coverage for gene therapy work: Mivision the ophthalmic journal – ‘Grant for CERA start-up aiming to switch on sight’; Eyesmart news – ‘Australian Startup Mirugen Secures Grant to Advance Gene Therapy for Vision Restoration’; Retina UK – ‘Mirugen – Unlocking the Power of Retina Regeneration’; Insight news – ‘Funding boost for Aussie gene therapy start-up aiming to reverse eye damage’
- 2024 – Inspiring Leaders Seminar Series, Flinders University, Australia
- 2024 – St Vincent’s Institute seminar series, St Vincent’s Institute of Medical Research
- 2022 – Research seminar, Department of Ophthalmology, University of Bonn, Germany
- 2022 – Research seminar, Save Sight Institute, Sydney Eye Hospital, Australia
- 2022 – ACMD link seminar, Aikenhead Centre for Medical Discovery, Australia
- 2021 – Research seminar, National Stem Cell Conversations, Australian Society of Stem Cell Research
Funding Leverage
- Following the award of the Retina Australia grant, the cell reprogramming project was subsequently awarded:
- a NHMRC ideas grant ($979,264)
- MRFF Stem Cell Therapies Mission grant ($587,569) and a
- National Stem Cell Foundation of Australia ($100,000)
- The spin-off Mirugen was awarded the MRFF CUREator grant ($500,000) and the MRFF CUREator+ grant ($1.92M), as well as commercial investment to further advance our pre-clinical development program.
- In addition, Associate Professor Wong and team’s findings enabled initiation of new cell reprogramming projects to treat retinal degeneration, which was awarded funding from the CASS Foundation ($62,000) and collaborative fundings with Japan (RIKEN, $119,180) and Germany (University of Bonn, $290,200).
Associate Professor Wong comments:
“The project has been a big success and we were awarded a total of >$4.5M competitive funding following the Retina Australia grant – the Retina Australia grant has certainly contributed significantly to our journey to develop this novel retinal gene therapy to treat retinitis pigmentosa!”
https://retinaaustralia.com.au/research-grant-impact-highlight-associate-professor-raymond-wong/
Other Blogs

Research Updates on Inherited Retinal Diseases: ARVO 2025 Summary
For those living with inherited retinal diseases (IRDs), and...

New Research: The burden of X-linked retinitis pigmentosa (XLRP) on patient experience and patient-reported outcomes
X-linked retinitis pigmentosa (XLRP) is considered one of the...

New Research: The Impacts of Caregiving for Patients with X-Linked RP
X-linked retinitis pigmentosa (XLRP) is considered one of the...